Integrase inhibitors in the treatment of HIV-1 infection

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

(2010) Roy T. Steigbigel et al.   CLINICAL INFECTIOUS DISEASES

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study

(2009) William Towner et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

(2009) Martin Markowitz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

(2008) Marianne Harris et al.   AIDS

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

(2008) B. Roquebert et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE